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Background: Ivabradine, a specific If current inhibitor, improves prognosis in patients with chronic heart failure (CHF) and is recommended by ESC 
Guidelines for symptomatic CHF patients with elevated heart rate (HR) on evidence-based or maximum tolerated doses of β-blocker (BB) and RAAS 
antagonists. However, many patients tolerate BB poorly and few reach target dose.
objective: To compare the uptitration of carvedilol alone or with ivabradine in CHF patients.
methods: 41 patients (27 men) in sinus rhythm with previous MI, CHF (NYHA class II-III), and HR ≥70 bpm. Participants had not taken BB for ≥2 
months and were ivabradine-naïve. Patients were divided into 2 groups: 21 patients on carvedilol, and 20 patients on carvedilol and ivabradine. 
Carvedilol 3.125 mg bid was initiated on top of standard therapy, and doubled every 2 weeks until 25 mg bid or maximum tolerated dose was 
reached. Ivabradine 5 mg bid was prescribed 1-2 days after carvedilol initiation, and uptitrated to 7.5 mg bid 1 month later if HR ≥70 bpm. The final 
visit was at 3 months.
results: Mean age was 61.7±10.4 years, baseline HR was 83.8±11.6 bpm, and baseline systolic BP was 133.3±13.8 mm Hg. Sex, age, and severity of 
CHF were similar in both groups. The most common reasons for not reaching BB target dose were hypotension, dizziness, and worsening CHF.
conclusions: Addition of ivabradine to carvedilol in patients with CHF resulted in a shorter BB uptitration period, higher final BB dose, greater HR 
reduction, and better exercise capacity.
Results
Carvedilol Carvedilol + ivabradine
Patients at ≥50% of carvedilol target dose, n (%) 8 (38%) 16 (80%)*
Duration of carvedilol uptitration, months 2.7±0.7 1.9±0.5*
Final dose of carvedilol, mg/day 29.6±6.2 37.4±8.4*
Δ HR, bpm 7.2±2.4 12.9±3.5*
Δ distance in the 6-min walking test, m 32.4±11.7 68.3±12.7*
*P<0.05
